tavapadon – Lab DB

Pharmaceutical R&D

Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data

Teuku Ryan Apr 24, 2026 0

AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…

Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data

YOU MAY HAVE MISSED

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286

Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition

Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation